Literature DB >> 26785141

Extracorporeal liver support devices for listed patients.

Karla C L Lee1, Vanessa Stadlbauer2, Rajiv Jalan3.   

Abstract

An alternative to liver transplantation for patients with liver failure remains an unmet need. In acute liver failure, the ideal extracorporeal liver support device (ELSD) would replace the functions of the failing liver in order to permit spontaneous recovery, given the incredible regenerative potential of the liver, negating the need for transplantation. In acute-on-chronic liver failure, an ELSD would ideally support hepatic function until a recovery to liver function before acute decompensation or until liver transplantation. In decompensated cirrhosis, an ELSD could again be used to support hepatic function until transplant. In addition, ELSDs may have the potential to treat the multiorgan failure that accompanies liver failure including hepatic encephalopathy, renal failure, and immune dysfunction or indeed potential to promote liver regeneration. Creation of an extracorporeal bioartificial liver able to completely replace liver function remains an unmet need. This review will describe a number of technologies suitable for clinical trials in humans, which have resulted from decades of engineering and biological research to develop a bioreactor able to adequately sustain functional hepatocytes. In addition, this review will describe artificial liver support devices that are primarily designed to replace the detoxifying functions of the liver and will consider the current data available or studies required to support their use in liver failure patients on the transplant waiting list. Liver Transplantation 22 839-848 2016 AASLD.
© 2016 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2016        PMID: 26785141     DOI: 10.1002/lt.24396

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  9 in total

1.  Prolonged Survival Following Pig-to-Primate Liver Xenotransplantation Utilizing Exogenous Coagulation Factors and Costimulation Blockade.

Authors:  J A Shah; M S Patel; N Elias; N Navarro-Alvarez; I Rosales; R A Wilkinson; N J Louras; M Hertl; J A Fishman; R B Colvin; A B Cosimi; J F Markmann; D H Sachs; P A Vagefi
Journal:  Am J Transplant       Date:  2017-06-06       Impact factor: 8.086

Review 2.  Management of acute liver failure in intensive care.

Authors:  Riaz Aziz; Jennifer Price; Banwari Agarwal
Journal:  BJA Educ       Date:  2021-01-14

Review 3.  Extracorporeal renal and liver support in pediatric acute liver failure.

Authors:  Bogdana Sabina Zoica; Akash Deep
Journal:  Pediatr Nephrol       Date:  2020-06-05       Impact factor: 3.714

Review 4.  Therapeutic plasma exchange in children with acute liver failure (ALF): is it time for incorporation into the ALF armamentarium?

Authors:  Emma C Alexander; Akash Deep
Journal:  Pediatr Nephrol       Date:  2021-10-14       Impact factor: 3.651

5.  Alleviating liver failure conditions using an integrated hybrid cryogel based cellular bioreactor as a bioartificial liver support.

Authors:  Apeksha Damania; Mohsin Hassan; Nana Shirakigawa; Hiroshi Mizumoto; Anupam Kumar; Shiv K Sarin; Hiroyuki Ijima; Masamichi Kamihira; Ashok Kumar
Journal:  Sci Rep       Date:  2017-01-12       Impact factor: 4.379

6.  The role of insulin in transdifferentiated hepatocyte proliferation and function in serum-free medium.

Authors:  Ce Gu; Panpan Li; Wei Liu; Yan Zhou; Wen-Song Tan
Journal:  J Cell Mol Med       Date:  2019-04-04       Impact factor: 5.310

7.  Development of a genetically modified hepatoma cell line with heat-inducible high liver function.

Authors:  Hiroyuki Kitano; Yuki Nagae; Yoshinori Kawabe; Akira Ito; Masamichi Kamihira
Journal:  Cytotechnology       Date:  2021-02-24       Impact factor: 2.040

8.  Artificial Liver and Renal Support System for Cynomolgus Monkeys with Surgery-Induced Acute Renal Failure: A Preclinical Study.

Authors:  Lei Feng; Guolin He; Lei Cai; Chaoyi Fu; Yang Li; Jun Weng; Xiaolin Huo; Qing Peng; Yi Gao
Journal:  Biomed Res Int       Date:  2018-05-24       Impact factor: 3.411

Review 9.  Cell and Tissue Therapy for the Treatment of Chronic Liver Disease.

Authors:  Yaron Bram; Duc-Huy T Nguyen; Vikas Gupta; Jiwoon Park; Chanel Richardson; Vasuretha Chandar; Robert E Schwartz
Journal:  Annu Rev Biomed Eng       Date:  2021-05-11       Impact factor: 9.590

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.